Floatz logo

Rhil-7

Chronic Lymphocytic Leukemia (CLL)

Medical College of WisconsinPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Chronic Lymphocytic Leukemia (CLL) cohort.

Asset / SponsorPhaseRating
Ppsv23
Tampere University Hospital
Phase 4BB
OTLERTUZUMAB
Aptevo Therapeutics
Phase 1/2B
Immucillin H
BioCryst Pharmaceuticals
Phase 2B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CD19 (ANTIGEN)) (SYNTHETIC HUMAN MONOCLONAL MEDI-551 HEAVY CHAIN), DISULFIDE WITH SYNTHETIC HUMAN MONOCLONAL MEDI-551 .KAPPA.-CHAIN, DIMER
MedImmune LLC
Phase 2B
gsk2110183
University Health Network, Toronto
Phase 2B

View all 39 →

Same molecule, other indications

Rhil-7 is also rated in:

B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
62 / 100
View asset →
Lymphoma, Non-hodgkinsDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →